Levitt David G, Levitt Michael D
Department of Integrative Biology and Physiology, University of Minnesota.
Research Service, Veterans Affairs Medical Center, Minneapolis, MN, USA.
Clin Exp Gastroenterol. 2018 May 24;11:193-215. doi: 10.2147/CEG.S160921. eCollection 2018.
Increased blood ammonia (NH) is an important causative factor in hepatic encephalopathy, and clinical treatment of hepatic encephalopathy is focused on lowering NH. Ammonia is a central element in intraorgan nitrogen (N) transport, and modeling the factors that determine blood-NH concentration is complicated by the need to account for a variety of reactions carried out in multiple organs. This review presents a detailed quantitative analysis of the major factors determining blood-NH homeostasis - the N metabolism of urea, NH, and amino acids by the liver, gastrointestinal system, muscle, kidney, and brain - with the ultimate goal of creating a model that allows for prediction of blood-NH concentration. Although enormous amounts of NH are produced during normal liver amino-acid metabolism, this NH is completely captured by the urea cycle and does not contribute to blood NH. While some systemic NH derives from renal and muscle metabolism, the primary site of blood-NH production is the gastrointestinal tract, as evidenced by portal vein-NH concentrations that are about three times that of systemic blood. Three mechanisms, in order of quantitative importance, release NH in the gut: 1) hydrolysis of urea by bacterial urease, 2) bacterial protein deamination, and 3) intestinal mucosal glutamine metabolism. Although the colon is conventionally assumed to be the major site of gut-NH production, evidence is reviewed that indicates that the stomach (via metabolism) and small intestine and may be of greater importance. In healthy subjects, most of this gut NH is removed by the liver before reaching the systemic circulation. Using a quantitative model, loss of this "first-pass metabolism" due to portal collateral circulation can account for the hyperammonemia observed in chronic liver disease, and there is usually no need to implicate hepatocyte malfunction. In contrast, in acute hepatic necrosis, hyperammonemia results from damaged hepatocytes. Although muscle-NH uptake is normally negligible, it can become important in severe hyperammonemia. The NH-lowering actions of intestinal antibiotics (rifaximin) and lactulose are discussed in detail, with particular emphasis on the seeming lack of importance of the frequently emphasized acidifying action of lactulose in the colon.
血氨(NH)升高是肝性脑病的重要致病因素,肝性脑病的临床治疗主要集中在降低血氨水平。氨是器官内氮(N)转运的核心元素,由于需要考虑多个器官中发生的各种反应,因此对决定血氨浓度的因素进行建模较为复杂。本综述对决定血氨稳态的主要因素进行了详细的定量分析,这些因素包括肝脏、胃肠道系统、肌肉、肾脏和大脑对尿素、氨和氨基酸的氮代谢,最终目标是创建一个能够预测血氨浓度的模型。虽然在正常肝脏氨基酸代谢过程中会产生大量的氨,但这些氨会被尿素循环完全捕获,不会导致血氨升高。虽然一些全身性氨来源于肾脏和肌肉代谢,但血氨产生的主要部位是胃肠道,门静脉血氨浓度约为全身血液的三倍就证明了这一点。肠道释放氨的机制按重要性排序有三种:1)细菌脲酶水解尿素;2)细菌蛋白质脱氨;3)肠黏膜谷氨酰胺代谢。虽然传统上认为结肠是肠道氨产生的主要部位,但有证据表明胃(通过代谢)、小肠可能更为重要。在健康受试者中,大部分肠道氨在进入体循环之前就被肝脏清除了。使用定量模型,门静脉侧支循环导致的这种“首过代谢”丧失可解释慢性肝病中观察到的高氨血症,通常无需涉及肝细胞功能障碍。相反,在急性肝坏死中,高氨血症是由受损肝细胞引起的。虽然正常情况下肌肉摄取氨可忽略不计,但在严重高氨血症时可能变得重要。本文详细讨论了肠道抗生素(利福昔明)和乳果糖降低血氨的作用,特别强调了乳果糖在结肠中常被强调的酸化作用似乎并不重要。